Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies; and patient-specific therapies for dispensing individually dosed tablets. The company was founded in 2016 and is based in Berlin, Germany.
Revenue of Medios AG (ILM1.DE)
Revenue in 2023 (TTM): $1.93 B
According to Medios AG's latest financial reports the company's current revenue (TTM) is $1.93 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Medios AG
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $1.93 B | $56.2 M | $54.04 M | $31.78 M | $20.35 M |
| 2022 | $1.74 B | $115.63 M | $55.53 M | $30.1 M | $19.83 M |
| 2021 | $1.47 B | $74.09 M | $37.48 M | $14.69 M | $8.01 M |
| 2020 | $677.92 M | $40.66 M | $14.2 M | $9.63 M | $5.98 M |
| 2019 | $559.18 M | $36.82 M | $17.61 M | $15.39 M | $10.56 M |
| 2018 | $354.71 M | $25.02 M | $9.26 M | $7.98 M | $4.68 M |
| 2017 | $274.43 M | $18.79 M | $7.89 M | $7.26 M | $4.47 M |
| 2016 | $144.13 M | $8.04 M | $-792,145 | $-2,284,643 | $-3,431,211 |
| 2015 | $146 | $-61,341,328 | $-172,405 | $-174,054 | $-174,054 |
| 2014 | $4.85 K | $4.85 K | $-35,552 | $-35,851 | $-35,885 |
| 2013 | $353 | $353 | $-182,714 | $-178,702 | $-178,702 |
| 2012 | $38.11 K | $38.11 K | $-205,459 | $-220,496 | $-220,495 |
| 2011 | $1.49 M | $311.19 K | $258.2 K | $ | $ |
| 2010 | $1.12 M | $1.44 M | $-178,704 | $ | $ |